Cellular Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination Schemes Authorized by the Chilean Ministry of Health in January 2022
Primer Autor |
Tabilo Valenzuela, Paz Beatriz
|
Co-autores |
Flores Balter, Gabriela
Saint-Pierre Contreras, Gustavo
Conei Valencia, Daniel
Moreno Calderon, Catalina
Bohle Venegas, Constanza
Guajardo Rivera, Marcia
Silva Ojeda, Francisco
Vial Covarrubias, Maria Jesus
|
Título |
Cellular Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination Schemes Authorized by the Chilean Ministry of Health in January 2022
|
Editorial |
MDPI
|
Revista |
LIFE-BASEL
|
Lenguaje |
en
|
Resumen |
In December 2019, a case of atypical pneumonia was reported in Wuhan, China. It was named COVID-19 and caused by SARS-CoV-2. In a few months, scientific groups around the world developed vaccines to reduce the disease's severity. The objective was to evaluate the humoral and cellular immune response post immunization with three different vaccination schedules administered in Chile until January 2022. Sixty volunteers were recruited with a three-dose schedule, who had no history of infection nor close contact with a positive patient. IgG against the spike antigenic domain was detected, and the neutralization capacity against two groups of variants, Original/Alpha and Beta/Gamma, was also measured. Finally, the cellular response with interferon release was measured through IGRA. Results showed that there were significant differences in the neutralizing antibodies for the original and alpha variant when comparing three Comirnaty doses with Coronavac and Vaxzevria. A high number of reactive subjects against the different SARS-CoV-2 variants, alpha, gamma, and delta, were observed, with no significant differences between any of the three schemes, confirming the existence of a cellular immune response against SARS-CoV-2. In conclusion, the three vaccine schemes generated a cellular immune response in these volunteers.
|
Tipo de Recurso |
artículo original
|
doi |
10.3390/life12040534
|
Formato Recurso |
PDF
|
Palabras Claves |
SARS-CoV-2
COVID-19 vaccines
cell-mediated immunity
interferon-gamma release assays
SARS-COV-2
BNT162B2
RISK
|
Ubicación del archivo | |
Categoría OCDE |
Biología
Microbiología
|
Materias |
SARS-CoV-2
vacunas COVID-19
inmunidad mediada por células
ensayos de liberación de interferón-gamma
SARS-COV-2
BNT162B2
RISK
|
Título de la cita (Recomendado-único) |
Cellular Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination Schemes Authorized by the Chilean Ministry of Health in January 2022
|
Identificador del recurso (Mandatado-único) |
artículo original
|
Versión del recurso (Recomendado-único) |
version publicada
|
License |
CC BY 4.0
|
Condición de la licencia (Recomendado-repetible) |
CC BY 4.0
|
Derechos de acceso |
acceso abierto
|
Access Rights |
acceso abierto
|
Id de Web of Science |
WOS:000786930600001
|
- Colecciones
- Colección Publicaciones Científicas